Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]
Discontinued
Reference number: GID-TA10543
The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma.
Please note that following on from advice received from the company regarding the regulatory timelines , NICE has decided to suspend this appraisal from its current work programme.
As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes.